Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort

References

• Colombel JF, Mahadevan U. Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology. 2017;152(2):309–312.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Svartz N. Treatment of ulcerative colitis with salazopyrin. Sem Hop. 1948;24(52):1677.
   PubMedGoogle Scholar
• Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982;17(3):389–393.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000544.
   PubMedGoogle Scholar
• Godat S, Fournier N, Safroneeva E, et al. Frequency and type of drug-related side effects necessitating treatment discontinuation in the swiss inflammatory bowel disease cohort. Eur J Gastroenterol Hepatol. 2018;30(6):612–620.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–1048.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960;1:217–222.
   PubMed Web of Science ®Google Scholar
• Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust. 1962;49(2)(2):592–593.
   PubMed Web of Science ®Google Scholar
• Bean RH. Treatment of ulcerative colitis with antimetabolites. Br Med J. 1966;1(5495):1081–1084.
   PubMed Web of Science ®Google Scholar
• Acheson ED. ED. On the mortality ascribed to ulcerative colitis. J Chronic Dis. 1959;10:469–480.
   PubMedGoogle Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400. e393.
   PubMed Web of Science ®Google Scholar
• Stournaras E, Qian W, Pappas A, et al. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut. 2021;70(4):677–686.
   PubMed Web of Science ®Google Scholar
• Biemans VBC, Savelkoul E, Gabriels RY, et al. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2020;51(11):1076–1086.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(2):331–342.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for crohn's disease. Crohn's disease cA2 study group. N Engl J Med. 1997;337(15):1029–1035.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24(2):167–182.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Curran T, Alosilla M, et al. Mortality is rare following elective and non-elective surgery for ulcerative colitis, but mild postoperative complications are common. Dig Dis Sci. 2018;63(3):713–722.
   PubMed Web of Science ®Google Scholar
• Messenger DE, Mihailovic D, MacRae HM, et al. Subtotal colectomy in severe ulcerative and crohn's colitis: what benefit does the laparoscopic approach confer? Dis Colon Rectum. 2014;57(12):1349–1357.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and crohn’s disease. Aliment Pharmacol Ther. 2013;37(9):895–904.
   PubMed Web of Science ®Google Scholar
• Leeds IL, Sundel MH, Gabre-Kidan A, et al. Outcomes for ulcerative colitis with delayed emergency colectomy are worse when controlling for preoperative risk factors. Dis Colon Rectum. 2019;62(5):600–607.
   PubMed Web of Science ®Google Scholar
• Oresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9(1):4–25.
   PubMed Web of Science ®Google Scholar
• Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for crohn's disease. J Crohns Colitis. 2018;12(1):1–16.
   PubMed Web of Science ®Google Scholar
• Sjoberg D, Holmstrom T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala region of Sweden 2005–2009 - Results from the IBD cohort of the Uppsala region (ICURE). J Crohns Colitis. 2013;7(9):e351-357–e357.
   Web of Science ®Google Scholar
• Sjoberg D, Holmstrom T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year - results from the IBD cohort of the Uppsala region (ICURE) of Sweden 2005–2009. J Crohns Colitis. 2014;8(3):215–222.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Ronnblom A, Karlbom U. Clinical course of crohn’s disease in a population-based cohort in Uppsala county followed for 10 years. Scand J Gastroenterol. 2020;55:1301–1307.
   PubMed Web of Science ®Google Scholar
• Ronnblom A, Karlbom U. Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. Scand J Gastroenterol. 2021;56:403–409.
   PubMed Web of Science ®Google Scholar
• Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851–870.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24(2):157–165.
   PubMed Web of Science ®Google Scholar
• Foster RA, Zander DS, Mergo PJ, et al. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003;9(5):308–315.
   PubMed Web of Science ®Google Scholar
• Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest. 1992;101(5):1469–1471.
   PubMed Web of Science ®Google Scholar
• Freeman HJ, Freeman KJ. Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in crohn's disease. Can J Gastroenterol. 2000;14(2):138–143.
   PubMed Web of Science ®Google Scholar
• Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology. 1989;96(1):62–67.
   PubMed Web of Science ®Google Scholar
• Rolston VS, Patel AV, Learch TJ, et al. Prevalence and associations of avascular necrosis of the hip in a large well-characterized cohort of patients with inflammatory bowel disease. J Clin Rheumatol. 2019;25(1):45–49.
   PubMed Web of Science ®Google Scholar
• Simsek M, Deben DS, Horjus CS, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther. 2019;50(1):54–65.
   PubMed Web of Science ®Google Scholar
• Hibiya S, Matsuyama Y, Fujii T, et al. 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2021;53(1):103–113.
   PubMed Web of Science ®Google Scholar
• Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664–680.
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686.
   PubMed Web of Science ®Google Scholar
• Malham M, Jakobsen C, Hald M, et al. Editorial: suicide and IBD-a call to action. Authors’ reply. Aliment Pharmacol Ther. 2019;50(1):106–107.
   PubMed Web of Science ®Google Scholar
• Malham M, Jakobsen C, Paerregaard A, et al. The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study. Aliment Pharmacol Ther. 2019;50(1):33–39.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–451.
   PubMed Web of Science ®Google Scholar
• Butwicka A, Olen O, Larsson H, et al. Association of Childhood-Onset inflammatory bowel disease with risk of psychiatric disorders and suicide attempt. JAMA Pediatr. 2019;173(10):969.
   PubMed Web of Science ®Google Scholar
• Available from: https://cancercentrum.se/globalassets/cancerdiagnoser/tjock–och-andtarm-anal/kvalitetsregister/tjock–och-andtarm-2020/kolonrapport-2019.pdf
   Google Scholar
• Available from: https://cancercentrum.se/globalassets/cancerdiagnoser/tjock–och-andtarm-anal/kvalitetsregister/tjock–och-andtarm-2020/rektalrapport-2019.pdf
   Google Scholar